Drug-resistant pneumonia poses a significant challenge in intensive care units, with limited treatment options available. Particularly concerning is Pseudomonas aeruginosa, responsible for approximately 20% of hospital-acquired pneumonia cases, often exhibiting resistance to multiple antibiotics. A promising development in this fight comes from researchers at Massachusetts General Hospital in Boston, affiliated with Harvard Medical School, who suggest that inhaled nitric oxide, a gas commonly used in neonatal care, could play a crucial role in combating these tough infections.
In a recent study published in Science Translational Medicine, the researchers found that high doses of inhaled nitric oxide significantly reduced drug-resistant Pseudomonas in an animal model that closely mimicked a human ICU environment. Nitric oxide is naturally produced in the body and is typically administered at lower doses (20-80 parts per million) to dilate blood vessels in the lungs of patients suffering from acute respiratory failure. Lorenzo Berra, an associate professor of anaesthesia at Harvard Medical School and a senior author of the study, explained that their decision to use higher concentrations was guided by previous research. “At the low doses commonly used in clinical practice, nitric oxide mainly acts as a selective pulmonary vasodilator,” he noted, adding that a 2021 study indicated a threshold of 300 ppm might be necessary for antimicrobial effects.
The study involved sixteen ventilated pigs suffering from pneumonia caused by multidrug-resistant Pseudomonas. The researchers directly introduced the bacteria into the animals’ lungs, providing them with intensive care for three days. Half of the animals received inhaled nitric oxide at 300 ppm in short, repeated bursts, while the other half were given standard supportive care without antibiotics. Researchers continuously monitored oxygen levels, blood pressure, lung stiffness, and infection markers to assess the outcomes. The results were striking; the treated group exhibited a 99% reduction in bacterial counts in the lungs, alongside improvements in oxygenation and lung function.
Berra suggested that nitric oxide might help restore disrupted chemical signaling in the lungs, improving oxygen transfer and reducing the need for medications to maintain blood pressure. While these findings are encouraging, experts urge caution. Paul H. Edelstein, a professor of pathology and laboratory medicine at the University of Pennsylvania, emphasized that although the animals showed initial improvement, their lung function later deteriorated while still receiving treatment. He raised concerns about potential toxic effects of nitric oxide and questioned how long the antimicrobial effects might last. “While 99% sounds impressive, that still leaves millions of organisms, which could lead to a quick rebound once treatment ceases,” he warned.
Additionally, to ensure safety, the researchers conducted a small phase 1 trial involving ten healthy volunteers. Participants inhaled nitric oxide at 300 ppm three times a day for five days. Though methemoglobin levels rose temporarily, they remained below the 10% safety threshold without any serious adverse effects reported. The team also tested the gas on two critically ill ICU patients to evaluate its feasibility.
Despite promising initial results, proving efficacy in patient outcomes will require dedicated clinical trials, Berra explained, reiterating the need for this treatment to be used alongside standard care, not as a replacement. Practical challenges also exist; most hospitals aren’t equipped to deliver nitric oxide at high concentrations, necessitating specialized equipment and trained personnel. Berra noted that “the biggest obstacle would be technical, operational, and monitoring, not biological.”
Edelstein affirmed that while the research represents a vital first step, further investigation is essential to confirm the treatment’s effectiveness and safety before excitement can be fully justified.
Tags: pneumonia, drug resistance, intensive care, nitric oxide, Pseudomonas aeruginosa, clinical research, health science, Massachusetts General Hospital
Original Source: https://www.thehindu.com/sci-tech/science/can-a-common-hospital-gas-help-fight-drug-resistant-pneumonia/article70607199.ece
Category :
Tags:
Publish Date: 2026-02-11 07:00:00
